Form 4: Singular Genomics Systems Executive Exercises Stock Options
SEC Form 4 Filing
Eli N. Glezer, Chief Scientific Officer of Singular Genomics Systems, Inc., reports the acquisition of 7,500 shares of common stock through the exercise of restricted stock units.
Summary
- On March 15, 2024, Eli N. Glezer, the Chief Scientific Officer of Singular Genomics Systems, Inc., acquired 7,500 shares of common stock.
- This acquisition was a result of the settlement of vested Restricted Stock Units (RSUs).
- Each RSU represents the right to receive one share of the company's common stock.
- Following this transaction, Glezer directly owns 4,585,000 shares of common stock.
- Glezer also holds 90,000 Restricted Stock Units.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard insider transaction disclosure.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives regarding their holdings of company stock.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders, as it is a routine exercise of stock options by an executive.
- It provides transparency to shareholders regarding insider activity.
Key Dates
| Date | Description |
|---|---|
| 03/15/2023 | Date from which the RSUs vest in 16 equal quarterly installments |
| 03/15/2024 | Date of transaction: Eli N. Glezer acquired 7,500 shares of common stock through RSU settlement |
| 03/19/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.